Skip to content

SKYLINE study design: Efficacy and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer’s disease

Gantenerumab is a fully human IgG1 monoclonal antibody which promotes Fcγ receptor-mediated microglial phagocytosis of aggregated beta-amyloid. SKYLINE is a secondary prevention study to evaluate the safety and efficacy of gantenerumab in participants at risk for or at the earliest stages of AD (preclinical AD). The study will also include blood-based biomarker prescreening to enrich the main screening population for amyloid positivity.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically